With the onset of the COVID-19 crisis, CAMufacturing Solutions Inc. knew they needed to bring their expertise in additive manufacturing, or 3D printing, to support the rising demand for quick production of personnel protective equipment (PPE) for the health care community.
As of July 27, 2020, the number of COVID-19 confirmed cases worldwide reached 16.3 million people, with 114,000 cases in Canada. About two to eight percent of COVID-19 cases experience severe symptoms that lead to respiratory distress, organ failure, and even death. Currently, regular medical checkups consist of one-on-one phone calls to monitor the patient’s vital signs remotely.
When Gurudeeban Selvaraj and Satyavani Kaliamurthi came to Canada in 2019, they had no idea they would be creating both a preventative vaccine and a curing drug to address the millennium’s biggest pandemic.
When the COVID-19 pandemic was announced and the Government of Canada called upon researchers and businesses to develop solutions, Ramtin Rasoulinezhad answered.
A graduate student at Western University, Ramtin was working as a research engineer supported by Mitacs Accelerate . He was working on the Net Zero Energy Building project with AVL Manufacturing when CEO Vince Discristofaro selected him to work directly with the Hybrid Solution Division.